Full Breakdown
FDA Commissioner Defends mRNA Vaccine Funding Decisions
2/24/2026, 3:23:40 AM
FDA's Position on mRNA Vaccines
On February 23, 2026, U.S. Food and Drug Administration (FDA) Commissioner Marty Makary addressed the agency's stance on messenger RNA (mRNA) vaccines during an event focused on accelerating gene therapy approvals for rare diseases. Makary affirmed the FDA's support for mRNA technology, highlighting the agency's previous approvals of two mRNA vaccines for respiratory syncytial virus (RSV) developed by Moderna and GlaxoSmithKline (GSK). He emphasized that while the FDA endorses mRNA vaccines, the financial burden of their development should not fall on U.S. taxpayers.
Funding Cuts and Rationale
Makary's comments followed a significant shift in funding priorities by the U.S. Department of Health and Human Services (HHS), which had previously allocated over $700 million to Moderna for mRNA vaccine development aimed at pandemic threats, including bird flu. In August 2025, HHS decided to wind down its mRNA vaccine initiatives, a move that Makary defended by stating that the pharmaceutical companies involved, such as Moderna, Pfizer, and BioNTech, have generated substantial profits—over $50 billion—allowing them to finance their own research. He argued that taxpayer dollars should be redirected to underfunded areas, particularly bespoke conditions and rare diseases.
Criticism of Funding Decisions
The decision to cut funding has faced criticism, particularly from figures like HHS Secretary Robert F. Kennedy Jr., who has expressed skepticism about the efficacy of mRNA vaccines against respiratory infections. Kennedy's stance contrasts with the prevailing scientific consensus supporting the effectiveness of these vaccines. Makary, however, dismissed concerns about a contradiction in the FDA's support for mRNA technology while reducing funding, asserting that the agency's commitment to mRNA remains strong.
Broader Implications
Makary's remarks underscore a broader debate regarding the role of government funding in vaccine development, especially in light of the financial successes of mRNA manufacturers. He suggested that the focus should shift towards funding research in areas that have historically received less attention, such as rare diseases, rather than continuing to support well-funded vaccine manufacturers.
Official Statements & Responses
In his defense of the FDA's funding decisions, Makary stated, "It doesn't have to be on the backs of American taxpayers," advocating for a strategic reallocation of resources to address unmet medical needs. He expressed a desire to see further data on the potential of mRNA technology in treating various conditions, including cancer, where companies like Moderna and Merck are exploring innovative treatments.
Verbatim Quotes
- “It doesn't have to be on the backs of American taxpayers," said Makary.” — Marty Makary, FDA Commissioner
- "The companies that made mRNA vaccines made over $50 billion; they can fund their own research." — Marty Makary, FDA Commissioner
This ongoing dialogue reflects the complexities of public health funding and the evolving landscape of vaccine development in the United States.
